| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | A3G; ARCD; ARP9; ARP-9; CEM15; CEM-15; MDS019; bK150C2.7; dJ494G10.1 |
| WB Predicted band size | 46 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human APOBEC3G |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于APOBEC3G抗体的示例参考文献(内容为虚构示例，仅供参考)：
---
1. **文献名称**：*Structural Insights into APOBEC3G Viral Restriction and Antibody Recognition*
**作者**：Smith, J. et al.
**摘要**：本研究通过X射线晶体学解析了APOBEC3G蛋白的结构，并开发了特异性单克隆抗体，验证了其在抑制HIV-1病毒复制中的关键表位，为基于抗体的治疗策略提供了理论基础。
2. **文献名称**：*Development of a High-Affinity Antibody Targeting APOBEC3G for HIV-1 Latency Reactivation*
**作者**：Lee, H. & Zhang, Y.
**摘要**：研究团队利用噬菌体展示技术筛选出靶向APOBEC3G的纳米抗体，证明其可逆转HIV-1潜伏感染并增强抗逆转录病毒疗法的效果，为清除病毒库提供了新工具。
3. **文献名称**：*APOBEC3G-Specific Antibodies as Biomarkers for Cancer Hypermutation*
**作者**：Wang, Q. et al.
**摘要**：通过免疫组化分析，发现APOBEC3G抗体可特异性识别多种癌症组织中的异常胞苷脱氨酶活性，提示其在肿瘤基因组不稳定性检测中的潜在临床应用。
4. **文献名称**：*Antibody-Mediated Inhibition of APOBEC3G Catalytic Activity in Viral Defense*
**作者**：Garcia, M. et al.
**摘要**：研究报道了一种阻断APOBEC3G酶活性的中和抗体，通过体外实验证实其可调控病毒基因组的突变频率，为平衡宿主防御与过度突变风险提供了新思路。
---
**备注**：以上文献为示例，实际引用请通过PubMed、Web of Science等学术数据库检索关键词(如“APOBEC3G antibody”“therapeutic targeting”等)获取真实研究。
APOBEC3G (apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G) is a member of the APOBEC protein family, known for its role in innate immunity against viral pathogens, particularly HIV-1. As a cytidine deaminase, APOBEC3G introduces hypermutations in viral DNA during reverse transcription, rendering viral genomes nonfunctional. However, HIV-1 counteracts this defense through its viral infectivity factor (Vif), which targets APOBEC3G for proteasomal degradation. Studying APOBEC3G's antiviral mechanisms and its interplay with Vif is critical for understanding viral pathogenesis and developing therapeutic strategies.
Antibodies against APOBEC3G are essential tools for detecting its expression, localization, and functional interactions in both physiological and pathological contexts. These antibodies enable researchers to investigate APOBEC3G's role in restricting retroviruses, endogenous retroelements, and other viruses, as well as its unintended contributions to genomic instability in cancer through off-target DNA deamination. Applications include Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation assays to study protein-protein interactions (e.g., APOBEC3G-Vif binding) or post-translational modifications.
Both monoclonal and polyclonal APOBEC3G antibodies are available, often validated for specificity across human and model organism samples. Their development has advanced research on host-virus coevolution, antiviral drug design (e.g., Vif inhibitors), and cancer biology. Researchers select antibodies based on epitope specificity, ensuring recognition of particular domains (e.g., the catalytic deaminase domain) or modified forms of APOBEC3G. Robust antibody validation remains crucial to avoid cross-reactivity with other APOBEC family members, given their structural similarities.
×
